The Experts below are selected from a list of 166891959 Experts worldwide ranked by ideXlab platform
Xinxin Ding - One of the best experts on this subject based on the ideXlab platform.
-
hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium induced colitis mouse model
Acta Pharmaceutica Sinica B, 2020Co-Authors: Xinxin Ding, Qingyu Zhang, Xiaoyu FanAbstract:We examined the impact of gut inflammation on the expression of cytochrome P450 (P450) and other biotransformation genes in male mice using a dextran sulfate sodium (DSS)-induced colitis model. Several P450 isoforms, including CYP1A, CYP2B, CYP2C, and CYP3A, were down-regulated, accompanied by decreases in microsomal metabolism of diclofenac and nifedipine, in the liver and small intestine. The impact of the colitis on in vivo clearance of oral drugs varied for four different drugs tested: a small decrease for nifedipine, a relatively large decrease for lovastatin, but no change for pravastatin, and a large decrease in the absorption of cyclosporine A. To further assess the scope of influence of gut inflammation on gene expression, we performed genome-wide expression analysis using RNA-seq, which showed down-regulation of many CYPs, non-CYP phase-I enzymes, phase-II enzymes and transporters, and up-regulation of many other members of these gene families, in both liver and intestine of adult C57BL/6 mice, by DSS-induced colitis. Overall, our results indicate that gut inflammation suppresses the expression of many P450s and other biotransformation genes in the intestine and liver, and alters the pharmacokinetics for some but not all drugs, potentially affecting therapeutic efficacy or causing adverse effects in a drug-specific fashion.
-
impact of nicotine metabolism on nicotine s pharmacological effects and behavioral responses insights from a CYP2A 4 5 bgs null mouse
Journal of Pharmacology and Experimental Therapeutics, 2013Co-Authors: Kunzhi Jia, Xin Zhou, Sarah E Mccallum, Lindsay B Hough, Xinxin DingAbstract:Nicotine metabolism is believed to affect not only nicotine’s pharmacological effects but also nicotine addiction. As a key step toward testing this hypothesis, we have studied nicotine metabolism and nicotine’s pharmacological and behavioral effects in a novel knockout mouse model [named CYP2A(4/5)bgs-null] lacking a number of cytochrome P450 genes known to be or possibly involved in nicotine metabolism, including two CYP2A and all Cyp2b genes. We found that, compared with wild-type mice, the CYP2A(4/5)bgs-null mice showed >90% decreases in hepatic microsomal nicotine oxidase activity in vitro, and in rates of systemic nicotine clearance in vivo. Further comparisons of nicotine metabolism between CYP2A(4/5)bgs-null and CYP2A5-null mice revealed significant roles of both CYP2A5 and CYP2B enzymes in nicotine clearance. Compared with the behavioral responses in wild-type mice, the decreases in nicotine metabolism in the CYP2A(4/5)bgs-null mice led to prolonged nicotine-induced acute pharmacological effects, in that null mice showed enhanced nicotine hypothermia and antinociception. Furthermore, we found that the CYP2A(4/5)bgs-null mice developed a preference for nicotine in a conditioned place preference test, a commonly used test of nicotine’s rewarding effects, at a nicotine dose that was 4-fold lower than what was required by wild-type mice. Thus, CYP2A/2B-catalyzed nicotine clearance affects nicotine’s behavioral response as well as its acute pharmacological effects in mice. This result provides direct experimental support of the findings of pharmacogenetic studies that suggest linkage between rates of nicotine metabolism and smoking behavior in humans.
-
generation and characterization of a novel CYP2A 4 5 bgs null mouse model
Drug Metabolism and Disposition, 2013Co-Authors: Yuan Wei, Qingyu Zhang, Xin Zhou, Anwar Dunbar, Fang Liu, Kerri Kluetzman, Weizhu Yang, Xinxin DingAbstract:Knockout mouse models targeting various cytochrome P450 (P450 or CYP) genes are valuable for determining P450’s biologic functions, including roles in drug metabolism and chemical toxicity. In this study, a novel CYP2A(4/5)bgs-null mouse model was generated, in which a 1.2-megabase pair genomic fragment containing nine Cyp genes in mouse chromosome 7 (including, sequentially, CYP2A5, 2g1, 2b19, 2b23, 2a4, 2b9, 2b13, 2b10, and 2s1) are deleted, through Cre-mediated recombination in vivo. The resultant mouse strain was viable and fertile, without any developmental deficits or morphologic abnormalities. Deletion of the constitutive genes in the cluster was confirmed by polymerase chain reaction analysis of the genes and the mRNAs in tissues known to express each gene. The loss of this gene cluster led to significant decreases in microsomal activities toward testosterone hydroxylation in various tissues examined, including olfactory mucosa (OM), lung, liver, and brain. In addition, systemic clearance of pentobarbital was decreased in CYP2A(4/5)bgs-null mice, as indicated by >60% increases in pentobarbital-induced sleeping time, compared with wild-type (WT) mice. This novel CYP2A(4/5)bgs-null mouse model will be valuable for in vivo studies of drug metabolism and chemical toxicities in various tissues, including the liver, lung, brain, intestine, kidney, skin, and OM, where one or more of the targeted Cyp genes are known to be expressed in WT mice. The model will also be valuable for preparation of humanized mice that express human CYP2A6, CYP2A13, CYP2B6, or CYP2S1, and as a knockout mouse model for five non-P450 genes (Vmn1r184, Nalp9c, Nalp4a, Nalp9a, and Vmn1r185) that were also deleted.
-
CYP2A13 variable expression and role in human lung microsomal metabolic activation of the tobacco specific carcinogen 4 methylnitrosamino 1 3 pyridyl 1 butanone
Journal of Pharmacology and Experimental Therapeutics, 2007Co-Authors: Xiuling Zhang, Xinxin Ding, Jaime Dagostino, Qingyu Zhang, Linda B Von Weymarn, Sharon E MurphyAbstract:CYP2A13 is the most efficient cytochrome P450 enzyme in the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. The aims of this study were to determine the levels of CYP2A13 protein in human lung microsomes and to ascertain whether CYP2A13 plays any role in lung microsomal NNK metabolic activation. The expression of CYP2A6 and CYP2A13 was examined using a high-resolution immunoblotting method, following immunopurification with an anti-CYP2A5 antibody. We found that, of 116 human lung microsomal samples analyzed, ∼90% had detectable CYP2A6, whereas only 12% had detectable CYP2A13 with a detection limit of ∼2 fmol of CYP2A/mg protein. For the majority of microsomal samples analyzed, the level of CYP2A13 was found to be lower than the level of CYP2A6; overall, the highest level of CYP2A13 found (∼20 fmol/mg protein) was ∼10-fold lower than the highest level of CYP2A6 detected. Quantitative RNA-polymerase chain reaction analysis confirmed that the highly variable expression of the CYP2A proteins was consistent with variations in the levels of the corresponding CYP2A mRNAs in the same tissue samples. It is noteworthy that the level of CYP2A13, but not CYP2A6, was correlated with lung microsomal NNK metabolic activation activity. Furthermore, the addition of 8-methoxypsoralen, a CYP2A inhibitor, led to greater inhibition of NNK metabolic activation in microsomes containing relatively high levels of CYP2A13 than in samples containing no detectable CYP2A13. Taken together, these data indicate that human lung microsomal CYP2A13 is active in NNK metabolic activation. Therefore, individuals having relatively high levels of CYP2A13 expression will likely have an increased risk of developing smoking-related lung cancer.
-
immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa
Biochemical Pharmacology, 2003Co-Authors: Ying Chen, Qingyu Zhang, Yiqing Liu, Xiang Ren, Li Shi, Dazi Liu, Xinxin DingAbstract:The aim of the present study was to further characterize the expression of the CYP2A genes in human nasal mucosa. Fetal nasal tissues at 12-26 weeks of gestational age and surgical biopsy tissues from various regions of nasal cavity of adult patients were studied to determine whether CYP2A proteins can be detected by immunoblot in adults, whether higher levels of CYP2A proteins are present in adult than in fetal nasal mucosal microsomes, and whether CYP2A13 mRNA is more abundant than CYP2A6 mRNA in fetal nasal mucosa. In adults, immunoblot analysis detected CYP2A proteins in microsomes of the olfactory region from 8 of 10 individuals, but in none of the nasal microsomes of the respiratory region from 47 patients. Quantitative immunoblot analysis confirmed that CYP2A proteins are selectively expressed in the olfactory region in both adult and fetal tissues. Interestingly, the levels of CYP2A proteins in nasal microsomes were generally higher in fetuses than in adults. In the fetus, the level of CYP2A13 mRNA was much higher than that of CYP2A6 mRNA, as has been previously found in adult nasal mucosa. Immunohistochemical studies confirmed that, in the fetus, the CYP2A proteins are expressed in the supporting cells in the olfactory epithelium and in the Bowman's glands in the lamina propria. The prenatal expression of the CYP2A proteins in the olfactory mucosa suggests potential risks of developmental toxicity from maternally derived xenobiotics, since both CYP2A6 and CYP2A13 are known to be efficient in the metabolic activation of tobacco-specific nitrosamines and other respiratory toxicants.
Qingyu Zhang - One of the best experts on this subject based on the ideXlab platform.
-
hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium induced colitis mouse model
Acta Pharmaceutica Sinica B, 2020Co-Authors: Xinxin Ding, Qingyu Zhang, Xiaoyu FanAbstract:We examined the impact of gut inflammation on the expression of cytochrome P450 (P450) and other biotransformation genes in male mice using a dextran sulfate sodium (DSS)-induced colitis model. Several P450 isoforms, including CYP1A, CYP2B, CYP2C, and CYP3A, were down-regulated, accompanied by decreases in microsomal metabolism of diclofenac and nifedipine, in the liver and small intestine. The impact of the colitis on in vivo clearance of oral drugs varied for four different drugs tested: a small decrease for nifedipine, a relatively large decrease for lovastatin, but no change for pravastatin, and a large decrease in the absorption of cyclosporine A. To further assess the scope of influence of gut inflammation on gene expression, we performed genome-wide expression analysis using RNA-seq, which showed down-regulation of many CYPs, non-CYP phase-I enzymes, phase-II enzymes and transporters, and up-regulation of many other members of these gene families, in both liver and intestine of adult C57BL/6 mice, by DSS-induced colitis. Overall, our results indicate that gut inflammation suppresses the expression of many P450s and other biotransformation genes in the intestine and liver, and alters the pharmacokinetics for some but not all drugs, potentially affecting therapeutic efficacy or causing adverse effects in a drug-specific fashion.
-
generation and characterization of a novel CYP2A 4 5 bgs null mouse model
Drug Metabolism and Disposition, 2013Co-Authors: Yuan Wei, Qingyu Zhang, Xin Zhou, Anwar Dunbar, Fang Liu, Kerri Kluetzman, Weizhu Yang, Xinxin DingAbstract:Knockout mouse models targeting various cytochrome P450 (P450 or CYP) genes are valuable for determining P450’s biologic functions, including roles in drug metabolism and chemical toxicity. In this study, a novel CYP2A(4/5)bgs-null mouse model was generated, in which a 1.2-megabase pair genomic fragment containing nine Cyp genes in mouse chromosome 7 (including, sequentially, CYP2A5, 2g1, 2b19, 2b23, 2a4, 2b9, 2b13, 2b10, and 2s1) are deleted, through Cre-mediated recombination in vivo. The resultant mouse strain was viable and fertile, without any developmental deficits or morphologic abnormalities. Deletion of the constitutive genes in the cluster was confirmed by polymerase chain reaction analysis of the genes and the mRNAs in tissues known to express each gene. The loss of this gene cluster led to significant decreases in microsomal activities toward testosterone hydroxylation in various tissues examined, including olfactory mucosa (OM), lung, liver, and brain. In addition, systemic clearance of pentobarbital was decreased in CYP2A(4/5)bgs-null mice, as indicated by >60% increases in pentobarbital-induced sleeping time, compared with wild-type (WT) mice. This novel CYP2A(4/5)bgs-null mouse model will be valuable for in vivo studies of drug metabolism and chemical toxicities in various tissues, including the liver, lung, brain, intestine, kidney, skin, and OM, where one or more of the targeted Cyp genes are known to be expressed in WT mice. The model will also be valuable for preparation of humanized mice that express human CYP2A6, CYP2A13, CYP2B6, or CYP2S1, and as a knockout mouse model for five non-P450 genes (Vmn1r184, Nalp9c, Nalp4a, Nalp9a, and Vmn1r185) that were also deleted.
-
CYP2A13 variable expression and role in human lung microsomal metabolic activation of the tobacco specific carcinogen 4 methylnitrosamino 1 3 pyridyl 1 butanone
Journal of Pharmacology and Experimental Therapeutics, 2007Co-Authors: Xiuling Zhang, Xinxin Ding, Jaime Dagostino, Qingyu Zhang, Linda B Von Weymarn, Sharon E MurphyAbstract:CYP2A13 is the most efficient cytochrome P450 enzyme in the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. The aims of this study were to determine the levels of CYP2A13 protein in human lung microsomes and to ascertain whether CYP2A13 plays any role in lung microsomal NNK metabolic activation. The expression of CYP2A6 and CYP2A13 was examined using a high-resolution immunoblotting method, following immunopurification with an anti-CYP2A5 antibody. We found that, of 116 human lung microsomal samples analyzed, ∼90% had detectable CYP2A6, whereas only 12% had detectable CYP2A13 with a detection limit of ∼2 fmol of CYP2A/mg protein. For the majority of microsomal samples analyzed, the level of CYP2A13 was found to be lower than the level of CYP2A6; overall, the highest level of CYP2A13 found (∼20 fmol/mg protein) was ∼10-fold lower than the highest level of CYP2A6 detected. Quantitative RNA-polymerase chain reaction analysis confirmed that the highly variable expression of the CYP2A proteins was consistent with variations in the levels of the corresponding CYP2A mRNAs in the same tissue samples. It is noteworthy that the level of CYP2A13, but not CYP2A6, was correlated with lung microsomal NNK metabolic activation activity. Furthermore, the addition of 8-methoxypsoralen, a CYP2A inhibitor, led to greater inhibition of NNK metabolic activation in microsomes containing relatively high levels of CYP2A13 than in samples containing no detectable CYP2A13. Taken together, these data indicate that human lung microsomal CYP2A13 is active in NNK metabolic activation. Therefore, individuals having relatively high levels of CYP2A13 expression will likely have an increased risk of developing smoking-related lung cancer.
-
immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa
Biochemical Pharmacology, 2003Co-Authors: Ying Chen, Qingyu Zhang, Yiqing Liu, Xiang Ren, Li Shi, Dazi Liu, Xinxin DingAbstract:The aim of the present study was to further characterize the expression of the CYP2A genes in human nasal mucosa. Fetal nasal tissues at 12-26 weeks of gestational age and surgical biopsy tissues from various regions of nasal cavity of adult patients were studied to determine whether CYP2A proteins can be detected by immunoblot in adults, whether higher levels of CYP2A proteins are present in adult than in fetal nasal mucosal microsomes, and whether CYP2A13 mRNA is more abundant than CYP2A6 mRNA in fetal nasal mucosa. In adults, immunoblot analysis detected CYP2A proteins in microsomes of the olfactory region from 8 of 10 individuals, but in none of the nasal microsomes of the respiratory region from 47 patients. Quantitative immunoblot analysis confirmed that CYP2A proteins are selectively expressed in the olfactory region in both adult and fetal tissues. Interestingly, the levels of CYP2A proteins in nasal microsomes were generally higher in fetuses than in adults. In the fetus, the level of CYP2A13 mRNA was much higher than that of CYP2A6 mRNA, as has been previously found in adult nasal mucosa. Immunohistochemical studies confirmed that, in the fetus, the CYP2A proteins are expressed in the supporting cells in the olfactory epithelium and in the Bowman's glands in the lamina propria. The prenatal expression of the CYP2A proteins in the olfactory mucosa suggests potential risks of developmental toxicity from maternally derived xenobiotics, since both CYP2A6 and CYP2A13 are known to be efficient in the metabolic activation of tobacco-specific nitrosamines and other respiratory toxicants.
-
human cytochrome p450 CYP2A13 predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco specific carcinogen 4 methylnitrosamino 1 3 pyridyl 1 butanone
Cancer Research, 2000Co-Authors: Ziping Bao, Qingyu Zhang, Theresa J Smith, Junyan Hong, Xinxin DingAbstract:The human CYP2A subfamily comprises three genes, CYP2A6, CYP2A7, and CYP2A13. CYP2A6 is active toward many carcinogens and is the major coumarin 7-hydroxylase and nicotine C-oxidase in the liver, whereas CYP2A7 is not functional. The function of CYP2A13 has not been characterized. In this study, a CYP2A13 cDNA was prepared by RNA-PCR from human nasal mucosa and was translated using a baculovirus expression system. In a reconstituted system, the expressed CYP2A13 was more active than CYP2A6 in the metabolic activation of hexamethylphosphoramide, N,N-dimethylaniline, 2'-methoxyacetophenone, and N-nitrosomethylphenylamine but was much less active than CYP2A6 in coumarin 7-hydroxylation. Of particular interest, CYP2A13 was highly active in the metabolic activation of a major tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, with a catalytic efficiency much greater than that of other human cytochrome P450 isoforms examined previously. The tissue distribution of CYP2A13 was determined with isoform-specific RNA-PCR. CYP2A13 mRNA was detected in liver and a number of extrahepatic tissues, including nasal mucosa, lung, trachea, brain, mammary gland, prostate, testis, and uterus, but not in heart, kidney, bone marrow, colon, small intestine, spleen, stomach, thymus, or skeletal muscle. Quantitative PCR analysis further revealed that CYP2A13 mRNA is expressed at the highest level in the nasal mucosa, followed by the lung and the trachea. Together, these findings suggest that CYP2A13 plays important roles in xenobiotic toxicity and tobacco-related tumorigenesis in the human respiratory tract.
Hannu Raunio - One of the best experts on this subject based on the ideXlab platform.
-
CYP2A6 genetics structure regulation and function
Drug metabolism and drug interactions, 2012Co-Authors: Hannu Raunio, Minna RahnastorillaAbstract:The human CYP2A gene subfamily consists of three members, CYP2A6, CYP2A7, and CYP2A13. The CYP2A6 gene is highly polymorphic with approximately 40 annotated allelic variants. Individuals homozygous for some of these alleles have a total lack of CYP2A6 activity. The CYP2A6 protein is most abundant in liver and is expressed, although at much lower levels, in some other tissues, especially nasal mucosa. CYP2A6 differs from other human liver CYP forms in that it participates in the metabolism of very few currently used drugs. The two most relevant substrates for CYP2A6 are coumarin and nicotine. Coumarin is the marker substance for determining CYP2A6 activity both in vitro and in vivo. Approximately 80% of a nicotine dose is eliminated by CYP2A6, and there is a clear link between CYP2A6 genotypes, smoking behavior, and lung cancer risk.
-
expression of CYP2A genes in human liver and extrahepatic tissues
Biochemical Pharmacology, 1999Co-Authors: Satu Koskela, Frank J Gonzalez, Olavi Pelkonen, Pedro M Fernandezsalguero, Jukka Hakkola, Janne Hukkanen, Martti Sorri, Antti Saranen, Sisko Anttila, Hannu RaunioAbstract:Members of the human cytochrome P450 2A (CYP2A) subfamily are known to metabolize several promutagens, procarcinogens, and pharmaceuticals. In this study, the expression of the three genes found in the human CYP2A gene cluster was investigated in the liver and several extrahepatic tissues by gene-specific reverse transcriptase-polymerase chain reaction (RT-PCR). All three transcripts (CYP2A6, CYP2A7, and CYP2A13) were found to be present in liver. Quantitative RT-PCR analysis showed that CYP2A6 and CYP2A7 mRNAs were present at roughly equal levels in the liver, while CYP2A13 was expressed at very low levels. Two putative splicing variants of CYP2A7 were found in the liver. Nasal mucosa contained a low level of CYP2A6 and a relatively high level of CYP2A13 transcripts. Kidney, duodenum, lung, alveolar macrophages, peripheral lymphocytes, placenta, and uterine endometrium were negative for all transcripts. This survey gives a comprehensive picture of the expression pattern of CYP2A genes in liver and extrahepatic tissues and constitutes a basis for a search for functional CYP2A forms and their roles in chemical toxicity in liver and nasal mucosa.
-
characterisation and pcr based detection of a CYP2A6 gene deletion found at a high frequency in a chinese population
FEBS Letters, 1999Co-Authors: Mikael Oscarson, Hannu Raunio, Roman A Mclellan, Harriet Gullsten, Qunying Yue, Matti A Lang, Maria Luisa Bernal, Blanca Sinues, Ari Hirvonen, Olavi PelkonenAbstract:Cytochrome P450 2A6 is an important human hepatic P450 which activates pre-carcinogens, oxidises some drugs and constitutes the major nicotine C-oxidase. In fact, results have been presented in the literature which suggested a relationship between the distribution of defective CYP2A6 alleles and smoking behaviour as well as cigarette consumption. In the present report, we describe the structure of a novel CYP2A locus where the whole CYP2A6 gene has been deleted, resulting in an abolished cytochrome P450 2A6-dependent metabolism. The origin of this locus is apparently due to an unequal crossover event between the 3′-flanking region of the CYP2A6 and CYP2A7 genes. A rapid PCR-based method for the detection of the CYP2A6del allele was developed and the allele frequency was 15.1% among 96 Chinese subjects, but only 1.0% in Finns (n=100) and 0.5% in Spaniards (n=100). In the Chinese population, we did not detect any CYP2A6*2 alleles using an improved genotyping procedure, in contrast to the 11–20% previously reported. It is concluded that genotyping for the CYP2A6del allele is of great importance in studies correlating, for example, smoking behaviour, pre-carcinogen activation or drug metabolism to the CYP2A6 genotype, in particular when oriental populations are investigated.
-
the CYP2A subfamily function expression and genetic polymorphism
IARC scientific publications, 1999Co-Authors: Hannu Raunio, A Rautio, Olavi PelkonenAbstract:The CYP2A6 gene is one of the three members of the human CYP2A gene subfamily, the others being CYP2A7 and CYP2A13. The CYP2A6 enzyme catalyses the oxidation of several compounds that have clinical or toxicological interest, including pharmaceuticals, procarcinogens, and tobacco smoke constituents. CYP2A6 is expressed mainly in liver, and only trace amounts are found in extrahepatic tissues. Coumarin is a high-affinity substrate for CYP2A6, and a phenotyping test based on coumarin 7-hydroxylation has been developed. Two mutant alleles of the CYP2A6 gene have been found, i.e. CYP2A6*2 and CYP2A6*3. Homozygosity for both mutated alleles appears to confer a poor metabolizer (PM) phenotype, detectable by slow or non-existent 7-hydroxylation of coumarin. Very little is known about the inducibility and regulation of CYP2A6, but studies on the mouse orthologue, CYP2A5, have revealed novel pathways for induction. Since CYP2A6 polymorphism was found fairly recently, nothing is known presently about associations between variant CYP2A6 alleles and diseases or other adverse outcomes of exposure to toxins. Such studies, however, are clearly warranted, given the wide range of procarcinogens and other toxins metabolized by the CYP2A6 enzyme.
-
a genetic polymorphism in coumarin 7 hydroxylation sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
American Journal of Human Genetics, 1995Co-Authors: Pedro M Fernandezsalguero, Olavi Pelkonen, S M Hoffman, S Cholerton, H W Mohrenweiser, Hannu Raunio, A Rautio, J D Huang, W E EvansAbstract:A group of human cytochrome P450 genes encompassing the CYP2A, CYP2B, and CYP2F subfamilies were cloned and assembled into a 350-kb contig localized on the long arm of chromosome 19. Three complete CYP2A genes - CYP2A6, CYP2A7, and CYP2A13 - plus two pseudogenes truncated after exon 5 were identified and sequenced. A variant CYP2A6 allele that differed from the corresponding CYP2A6 and CYP2A7 cDNAs previously sequenced was found and was designated CYP2A6{nu}2. Sequence differences in the CY-P2A6{nu}2 gene are restricted to regions encompassing exons 3, 6, and 8, which bear sequence relatedness with the corresponding exons of the CYP2A7 gene, located downstream and centromeric of CYP2A6{nu}2, suggesting recent gene-conversion events. The sequencing of all the CYP2A genes allowed the design of a PCR diagnostic test for the normal CYP2A6 allele, the CYP2A6{nu}2 allele, and a variant - designated CYP2A6{nu}1 - that encodes an enzyme with a single inactivating amino acid change. These variant alleles were found in individuals who were deficient in their ability to metabolize the CYP2A6 probe drug coumarin. The allelic frequencies of CYP2A6{nu}1 and CYP2A6{nu}2 differed significantly between Caucasian, Asian, and African-American populations. These studies establish the existence of a new cytochrome P450 genetic polymorphism. 30 refs.,more » 4 figs., 2 tabs.« less
Xin Zhou - One of the best experts on this subject based on the ideXlab platform.
-
impact of nicotine metabolism on nicotine s pharmacological effects and behavioral responses insights from a CYP2A 4 5 bgs null mouse
Journal of Pharmacology and Experimental Therapeutics, 2013Co-Authors: Kunzhi Jia, Xin Zhou, Sarah E Mccallum, Lindsay B Hough, Xinxin DingAbstract:Nicotine metabolism is believed to affect not only nicotine’s pharmacological effects but also nicotine addiction. As a key step toward testing this hypothesis, we have studied nicotine metabolism and nicotine’s pharmacological and behavioral effects in a novel knockout mouse model [named CYP2A(4/5)bgs-null] lacking a number of cytochrome P450 genes known to be or possibly involved in nicotine metabolism, including two CYP2A and all Cyp2b genes. We found that, compared with wild-type mice, the CYP2A(4/5)bgs-null mice showed >90% decreases in hepatic microsomal nicotine oxidase activity in vitro, and in rates of systemic nicotine clearance in vivo. Further comparisons of nicotine metabolism between CYP2A(4/5)bgs-null and CYP2A5-null mice revealed significant roles of both CYP2A5 and CYP2B enzymes in nicotine clearance. Compared with the behavioral responses in wild-type mice, the decreases in nicotine metabolism in the CYP2A(4/5)bgs-null mice led to prolonged nicotine-induced acute pharmacological effects, in that null mice showed enhanced nicotine hypothermia and antinociception. Furthermore, we found that the CYP2A(4/5)bgs-null mice developed a preference for nicotine in a conditioned place preference test, a commonly used test of nicotine’s rewarding effects, at a nicotine dose that was 4-fold lower than what was required by wild-type mice. Thus, CYP2A/2B-catalyzed nicotine clearance affects nicotine’s behavioral response as well as its acute pharmacological effects in mice. This result provides direct experimental support of the findings of pharmacogenetic studies that suggest linkage between rates of nicotine metabolism and smoking behavior in humans.
-
generation and characterization of a novel CYP2A 4 5 bgs null mouse model
Drug Metabolism and Disposition, 2013Co-Authors: Yuan Wei, Qingyu Zhang, Xin Zhou, Anwar Dunbar, Fang Liu, Kerri Kluetzman, Weizhu Yang, Xinxin DingAbstract:Knockout mouse models targeting various cytochrome P450 (P450 or CYP) genes are valuable for determining P450’s biologic functions, including roles in drug metabolism and chemical toxicity. In this study, a novel CYP2A(4/5)bgs-null mouse model was generated, in which a 1.2-megabase pair genomic fragment containing nine Cyp genes in mouse chromosome 7 (including, sequentially, CYP2A5, 2g1, 2b19, 2b23, 2a4, 2b9, 2b13, 2b10, and 2s1) are deleted, through Cre-mediated recombination in vivo. The resultant mouse strain was viable and fertile, without any developmental deficits or morphologic abnormalities. Deletion of the constitutive genes in the cluster was confirmed by polymerase chain reaction analysis of the genes and the mRNAs in tissues known to express each gene. The loss of this gene cluster led to significant decreases in microsomal activities toward testosterone hydroxylation in various tissues examined, including olfactory mucosa (OM), lung, liver, and brain. In addition, systemic clearance of pentobarbital was decreased in CYP2A(4/5)bgs-null mice, as indicated by >60% increases in pentobarbital-induced sleeping time, compared with wild-type (WT) mice. This novel CYP2A(4/5)bgs-null mouse model will be valuable for in vivo studies of drug metabolism and chemical toxicities in various tissues, including the liver, lung, brain, intestine, kidney, skin, and OM, where one or more of the targeted Cyp genes are known to be expressed in WT mice. The model will also be valuable for preparation of humanized mice that express human CYP2A6, CYP2A13, CYP2B6, or CYP2S1, and as a knockout mouse model for five non-P450 genes (Vmn1r184, Nalp9c, Nalp4a, Nalp9a, and Vmn1r185) that were also deleted.
Robert J. Letcher - One of the best experts on this subject based on the ideXlab platform.
-
characterization and profiling of hepatic cytochromes p450 and phase ii xenobiotic metabolizing enzymes in beluga whales delphinapterus leucas from the st lawrence river estuary and the canadian arctic
Aquatic Toxicology, 2004Co-Authors: Melissa A Mckinney, Augustine Arukwe, Sylvain De Guise, Daniel Martineau, Pierre Beland, Andre Dallaire, Stephane Lair, Michel Lebeuf, Robert J. LetcherAbstract:Abstract Cytochromes P450 (CYP, phase I) and conjugating (phase II) enzymes can be induced by and influence the toxicokinetics (metabolism) and toxicity of xenobiotic contaminants in exposed organisms. Beluga whale (Delphinapterus leucas) from the endangered St. Lawrence (SL) River Estuary population exhibit deleterious health effects and various severe pathologies that have been associated with contaminant exposure. In contrast, such effects (e.g. reproductive and immunological impairment) are generally less frequent in less exposed populations in the Canadian Arctic (CA). In the present study, opportunistic sampling resulted in the collection immediately after death of liver tissue from a single female neonate SL beluga (SL6) and male and female CA beluga (n=10) from the Arviat region of western Hudson Bay, in addition to sampling of stranded carcasses of male and female SL beluga (n=5) at least 12 h postmortem. We immunologically characterized cross-reactive proteins of hepatic microsomal CYP1A, CYP2B, CYP3A, CYP2E, epoxide hydrolase (EH) and uridine diphosphoglucuronosyl transferase (UDPGT) isozymes. Cross-reactive proteins were found in all SL and CA beluga using anti-rat CYP1A1, anti-rainbow trout CYP3A, anti-human CYP2E1, anti-rabbit EH and anti-human UDPGT1A1 polyclonal antibodies (Abs), whereas faintly cross-reactive CYP2B proteins were only found in SL6 and the CA samples using an anti-rabbit CYP2B1 Ab. In corresponding catalytic activity assessments, only SL6 and all CA beluga microsomal samples exhibited CYP1A-mediated 7-ethoxyresorufin O-deethylase (EROD) activity (51–260 pmol/mg/min), CYP3A-mediated activity (113–899 pmol/mg/min) based on the formation of 6β-hydroxytestosterone using a testosterone hydroxylase assay, and UDPGT activity (830–4956 pmol/mg/min) based on 1-naphthylglucuronide formation. The marginal cross-reactivity with the anti-CYP2B1 Ab and lack of catalytically measurable hydroxytestosterone isomers associated with CYP2B-type activity in all the SL and CA animals is suggestive of low CYP2B-type enzyme expression in beluga. The absence of measurable total P450 enzyme levels and catalytic activities in samples from the stranded SL belugas suggested catalytically inactive enzymes as a consequence of tissue degradation related due to the time delay of sample collection after death. However, all SL and CA animals demonstrated similar, immunologically cross-reactive phase I and II hepatic enzyme profiles, which is suggestive of the importance of metabolism in the toxicokinetics and fate of xenobiotics in animals from both populations.
-
hepatic microsomal cytochrome p450 enzyme activity in relation to in vitro metabolism inhibition of polychlorinated biphenyls and testosterone in baltic grey seal halichoerus grypus
Environmental Toxicology and Chemistry, 2003Co-Authors: J P Boon, Madeleine Nyman, Wilma E Lewis, Martin Van Den Berg, Robert J. LetcherAbstract:Among other factors, cytochrome P450 (CYP) enzyme activity determines polychlorinated biphenyl (PCB) bioaccumulation, biotransformation, and toxicity in exposed species. We measured the oxidative metabolism in vitro of 12 PCB congeners, representing structural groups based on the number and position of the chlorine atoms, by the hepatic microsomes of one Baltic grey seal (Halichoerus grypus). Microsomal metabolism was observed for several PCBs with vicinal H atoms exclusively in the ortho and meta positions and without any ortho-Cl substituents (CB-15 [4,4'-Cl2] and CB-77 [3,3',4,4'-Cl4]), vicinal meta and para-H atoms (CB-52 [2,2',5,5'-Cl4], and -101 [2,2',4,5,5'-Cl5]) or with both characteristics in combination with either only one ortho-Cl (CB-26 [2,3',5-Cl3], CB-31 [2,4',5-Cl3]) or two ortho-Cl substituents (CB-44 [2,2',3,5'-Cl4]). To allocate PCB biotransformation to specific CYPs, the inhibitive effect of compounds with known CYP-specific inhibition properties was assessed on in vitro PCB metabolism and on regio- and stereospecific testosterone hydroxylase activities. Metabolic inhibition was considered relevant at concentrations < or = 1.0 microM because these inhibitors became decreasingly selective at higher concentrations. At < 1.0 microM, ellipticine (CYPIAI/2 inhibitor) selectively inhibited CB-15, -26, -31, and -77 metabolism, with no significant inhibition of CB-44, -52, and -101 metabolism. Inhibition of CB-52 and -101 metabolism by chloramphenicol (CYP2B inhibitor) started at 1.0 microM and maximized at about 100% at 10 microM. Ketoconazole (CYP3A inhibitor) appeared to selectively inhibit CB-26, -31, and -44 metabolism relative to CB-15, -77, and -52 at concentrations < or = 1.0 microM. Major testosterone metabolites formed in vitro were 2beta-(CYP3A), 6beta- (CYP3A, CYPIA), and 16beta- (CYP2B) hydroxytestosterone and androstenedione (CYP2B, CYP2C11). The CYP forms indicated are associated with the specific metabolism of testosterone in laboratory animals. Inhibition of 2beta- and 6beta-hydroxytestosterone formation at ellipticine and ketoconazole concentrations < or = 1.0 microM suggested that both inhibitors were good substrates of CYP3A-like enzymes in grey seal. Chloramphenicol (model for CYP2B) is apparently not a good inhibitor of CYPI A and CYP3A activities in grey seal because the chemical did not inhibit any metabolic route of testosterone at concentrations from 0.1 to 10 microM. Our findings demonstrated that at least CYP1A- and CYP3A-like enzymes in the liver of grey seals are capable of metabolizing PCBs with ortho-meta and/or meta-para vicinal hydrogens. A CYP2B form might also be involved, but this could not be proven by the results of our experiments. Defining the profiles of CYP enzymes that are responsible for PCB biotransformation is necessary to fully understand the bioaccumulation, toxicokinetics, and risk of PCB exposure in seals and other free-ranging marine mammals.
-
immunoquantitation and microsomal monooxygenase activities of hepatic cytochromes p4501a and p4502b and chlorinated hydrocarbon contaminant levels in polar bear ursus maritimus
Toxicology and Applied Pharmacology, 1996Co-Authors: Robert J. Letcher, Ross J Norstrom, Malcolm A. RamsayAbstract:Contamination of the Arctic ecosystem by anthropogenic compounds has resulted in exposure of polar bear (Ursus maritimus) to lipophilic chlorinated hydrocarbon contaminants (CHCs) accumulated through the marine food web. Liver samples were collected from 16 adult male polar bears in the Canadian arctic and subjected to chemical analysis for CHCs and metabolites, determination of alkoxyresorufinO-dealkylase activities, and immunoquantitation of cytochrome P450 (CYP) protein levels. We report on the relationships between the hepatic microsomal levels of immunoreactive CYP1A and CYP2B isozymes, catalytic activities, and hepatic CHC and metabolite concentrations in polar bear. We specifically explored the influence of several CHCs on the induction of hepatic CYP in polar bear and the potential use of immunoassay quantitation as a bioindicator of CHC exposure. Polychlorinated biphenyls (PCBs) classed as CYP1A and mixed CYP1A/CYP2B inducers accounted for about 25% of the total PCB residues present (18,680 ± 5053 ng/g lipid). CYP1A protein content correlated strongly with hepatic levels of PCBs, PCDDs (0.032 ± 0.018 ng/g lipid), and PCDFs (0.011 ± 0.007 ng/g lipid) and their corresponding toxic equivalents (TEQ, 0.377 ± 0.182 ng/g lipid). Mono-ortho-CB-156, CB-157, and CB-105 were the predominant TEQ contributors. Correlations between CYP2B protein content and CHC residue levels in polar bear liver suggested thatortho-chlorine-substituted PCBs and chlordanes were the major contributors to CYP2B induction. CYP1A and CYP2B contents were therefore good indicators of CHC exposure in polar bear liver. Ethoxyresorufin, pentoxyresorufin, and benzyloxyresorufinO-dealkylase activities increased with increasing CYP1A protein content up to protein levels of approximately 5 pmol/mg, suggesting that all three activities were primarily CYP1A-mediated. These results were substantiated by antibody inhibition experiments. In summary, immunoquantitated CYP1A and CYP2B isozymes are a more reliable measure of exposure to CHC inducers than alkoxyresorufinO-dealkylase activities in polar bear.
-
immunoquantitation and microsomal monooxygenase activities of hepatic cytochromes p4501a and p4502b and chlorinated hydrocarbon contaminant levels in polar bear ursus maritimus
Toxicology and Applied Pharmacology, 1996Co-Authors: Robert J. Letcher, Ross J Norstrom, Malcolm A. RamsayAbstract:Contamination of the Arctic ecosystem by anthropogenic compounds has resulted in exposure of polar bear (Ursus maritimus) to lipophilic chlorinated hydrocarbon contaminants (CHCs) accumulated through the marine food web. Liver samples were collected from 16 adult male polar bears in the Canadian arctic and subjected to chemical analysis for CHCs and metabolites, determination of alkoxyresorufinO-dealkylase activities, and immunoquantitation of cytochrome P450 (CYP) protein levels. We report on the relationships between the hepatic microsomal levels of immunoreactive CYP1A and CYP2B isozymes, catalytic activities, and hepatic CHC and metabolite concentrations in polar bear. We specifically explored the influence of several CHCs on the induction of hepatic CYP in polar bear and the potential use of immunoassay quantitation as a bioindicator of CHC exposure. Polychlorinated biphenyls (PCBs) classed as CYP1A and mixed CYP1A/CYP2B inducers accounted for about 25% of the total PCB residues present (18,680 ± 5053 ng/g lipid). CYP1A protein content correlated strongly with hepatic levels of PCBs, PCDDs (0.032 ± 0.018 ng/g lipid), and PCDFs (0.011 ± 0.007 ng/g lipid) and their corresponding toxic equivalents (TEQ, 0.377 ± 0.182 ng/g lipid). Mono-ortho-CB-156, CB-157, and CB-105 were the predominant TEQ contributors. Correlations between CYP2B protein content and CHC residue levels in polar bear liver suggested thatortho-chlorine-substituted PCBs and chlordanes were the major contributors to CYP2B induction. CYP1A and CYP2B contents were therefore good indicators of CHC exposure in polar bear liver. Ethoxyresorufin, pentoxyresorufin, and benzyloxyresorufinO-dealkylase activities increased with increasing CYP1A protein content up to protein levels of approximately 5 pmol/mg, suggesting that all three activities were primarily CYP1A-mediated. These results were substantiated by antibody inhibition experiments. In summary, immunoquantitated CYP1A and CYP2B isozymes are a more reliable measure of exposure to CHC inducers than alkoxyresorufinO-dealkylase activities in polar bear.
